The use of simvastatin with aromasin in an ovariectomized rat model: Effects on the skeletal system

Chang Gung Medical Journal

Volumn 33, Issue 5, 2010, Pages 509-514

  Chen, Sung Hsiung ^a   Chou, Fong Fu ^b   Ko, Jih Yang ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Aromasin; Bone mineral density; Simvastatin

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; EXEMESTANE; PHOSPHORUS; SIMVASTATIN; WATER;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CATABOLISM; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; LUMBAR SPINE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PHOSPHATE BLOOD LEVEL; RAT; TREATMENT DURATION;

ANDROSTADIENES; ANIMALS; AROMATASE INHIBITORS; BONE DENSITY; DISEASE MODELS, ANIMAL; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 78249250545     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Brodie AM, Wing LY. In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione. Steroids 1987;50:89-103.
2. Prichard RS, Hill ADK, Dijkstra B, McDermott EW, O'Higgins NJ. The prevention of breast cancer. Br J Surg 2003;90:772-83.
3. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
4. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase inhibitors in breast cancer prevention. Endocr Relat Cancer 1999;6:235-43.
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
6. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Mnutr KS, Nicholson GC. Statin use, bone mineral density, and facture risk: Geelong Osteoporosis Study. Arch Intern Med 2002;162:537-40.
7. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000;355:2218-9.
8. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001;280:874-7.
9. Chou FF, Huang SC, Chen SS, Wang PW, Huang PH, Wu KY. Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: A study in a rat model. Osteoporos Int 2006;17:936-41.
10. Yee AJM, Bae HW, Friess D, Roth SM, Whyne C, Robbin M, Johnstone B, Yoo JU. The use of simvastatin in rabbit posterolateral lumbar intertransverse process spine fusion. Spine J 2006;6:391-6.
11. Omar WA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-COA reductase inibitors. Ann Pharmacother 2001;35:1096-107.
12. Howell A, Dowsett M. Recent advances in endocrine therapy of breast cancer. BMJ 1997;315:863-6
13. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. The ATAC Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
14. Santen RJ, Harvey HA. Use of aromase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75-92.
15. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxfen as first-line therapy for advanced breast cancer in postmenopausal women: results of North American multicenter randomized trial. J Clin Oncol 2000;18:3758-76.
16. Bonneterre J, Buzdar A, Nabholtz JMA, Robertson JF, Thürlimann B, von Euler M, Sahmound T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as firstline therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 2001;92:2247-58.
17. Love RR. Breast cancer prevention. Oncologist 2002;7:100-2.
18. Grodstein F, Stampfer M. The epideminology for coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
19. Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998;7:65-78.
20. Neer RM, Arnaud CD, Zanchettu JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
21. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompean DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracture. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
22. Siris E, Adachi JD, Lu Y, Fuerst T, Cruns GG, Wong M, Harper KD, Genant HK. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple outcomes of raloxifen evaluation. Osteoporos Int 2002;13:907-13.
23. Oxlund H, Andreassen TT. Simvastatin given per orally to adult rats increases the compressive strength of vertebral bodies. J Bone Miner Res 2000;15S1:S549.
24. Oxlund H, Andereassen TT. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 2004;34:609-18.
25. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductose inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
26. Chan KA, Ardrade SE, Boles M, Buist DSM, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, Lacroix AI, Platt R. Inhibitors of hydroxymethyl glutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8.
27. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-6.